• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DCK Gene Record

  • Summary
  • Interactions
  • Claims
  • DCK 1633 Druggable Genome

    Alternate Names:

    1633
    DEOXYCYTIDINE KINASE
    DCK
    125450
    2704
    ENSG00000156136
    OTTHUMG00000129908
    P27707
    PA137

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:2.7.1.74
    Gene Biotype PROTEIN_CODING
    (2 More Sources)

    Gene Categories: Category Details

    KINASE
    DRUGGABLE GENOME
    ENZYME

    Publications:

    Shi JY et al., 2004, Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients., Pharmacogenetics
    Innoceta et al., 2002, Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells., Mol. Cell. Biochem.
    Agarwal et al., 1999, Collateral resistance of a dideoxycytidine-resistant cell line to 5-fluoro-2'-deoxyuridine., Biochem. Biophys. Res. Commun.
    Giovannetti et al., 2007, Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells., Pharmacol. Res.
    Thompson P et al., 2014, Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group., Cancer Chemother Pharmacol
    Yasui et al., 2004, Alteration in copy numbers of genes as a mechanism for acquired drug resistance., Cancer Res.
    Jordheim et al., 2005, [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues]., Bull Cancer
    Yao et al., 2010, [Correlation of deoxycytidine kinase gene expression with fludarabine resistance in patients with chronic lymphocytic leukemia]., Zhongguo Shi Yan Xue Ye Xue Za Zhi
    Zhang et al., 2006, The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation., Acta Crystallogr. D Biol. Crystallogr.
    Grie et al., 2000, Cytostatic and cytotoxic effects of (E)-2'-deoxy-2'-(fluoromethylene)-cytidine on a solid tumor and a leukemia cell line., Acta Biochim. Pol.
    Alvarellos ML et al., 2014, PharmGKB summary: gemcitabine pathway., Pharmacogenet Genomics
    Baker JA et al., 2013, Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase., Drug Metab Dispos
    Maréchal R et al., 2012, Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma., Gastroenterology
    Tanaka M et al., 2010, Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer., Cancer
    Kroep et al., 2002, Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity., Mol. Cancer Ther.
    Sabini et al., 2008, Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase., J. Med. Chem.
  • TEZACITABINE   DCK

    Interaction Score: 11.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10961690


    Sources:
    NCI

  • TETRAHYDROURIDINE   DCK

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17296311


    Sources:
    NCI

  • DEOXYCYTIDINE   DCK

    Interaction Score: 4.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11952160 10471381


    Sources:
    NCI

  • FLUDARABINE   DCK

    Interaction Score: 1.18

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name fludarabine phosphate,Fludara
    Novel drug target Established target

    PMIDs:
    15820918 20137114 16421443


    Sources:
    TdgClinicalTrial

  • CLADRIBINE   DCK

    Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18570408


    Sources:
    NCI

  • GEMCITABINE   DCK

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25162786 23230131 22705007 20665488 12477049


    Sources:
    PharmGKB

  • CAMPTOTHECIN   DCK

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14973057


    Sources:
    NCI

  • IDARUBICIN   DCK

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15564883


    Sources:
    PharmGKB

  • CYTARABINE   DCK

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15564883


    Sources:
    PharmGKB

  • LAMIVUDINE   DCK

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DAUNORUBICIN   DCK

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25119182


    Sources:
    PharmGKB

  • Ensembl: ENSG00000156136

    • Version: 101_38

    Alternate Names:
    DCK Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P27707

    • Version: January-2014

    Alternate Names:
    DCK Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:2.7.1.74

    Publications:

  • PharmGKB: DCK

    • Version: 18-August-2020

    Alternate Names:
    PA137 PharmGKB ID

    Gene Info:

    Publications:
    Thompson P et al., 2014, Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group., Cancer Chemother Pharmacol
    Shi JY et al., 2004, Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients., Pharmacogenetics
    Kroep et al., 2002, Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity., Mol. Cancer Ther.

  • NCI: DCK

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Agarwal et al., 1999, Collateral resistance of a dideoxycytidine-resistant cell line to 5-fluoro-2'-deoxyuridine., Biochem. Biophys. Res. Commun.
    Innoceta et al., 2002, Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells., Mol. Cell. Biochem.
    Grie et al., 2000, Cytostatic and cytotoxic effects of (E)-2'-deoxy-2'-(fluoromethylene)-cytidine on a solid tumor and a leukemia cell line., Acta Biochim. Pol.

  • HingoraniCasas: ENSG00000156136

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000156136 Gene Symbol
    DCK Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Pharos: DCK

    • Version: 01-February-2022

    Alternate Names:
    Deoxycytidine kinase Gene Name
    P27707 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE, ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21